



# Latent Tuberculosis Management in Liver Transplant Recipients: Insights from a Retrospective Analysis

Mohsen Aliakbarian <sup>1</sup>, Mahboobeh Ghasemzadeh Rahbardar <sup>1</sup>, Zeinab Barzegar Torghabeh <sup>1</sup>, Gholamhossein Faghani <sup>1</sup>, Rozita Khodashahi <sup>1, 2, \*</sup>

<sup>1</sup>Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>2</sup>Clinical Research Development Unit, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

\*Corresponding Author: Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Email: khodashahir@mums.ac.ir

Received: 7 December, 2024; Revised: 3 June, 2025; Accepted: 29 June, 2025

## Abstract

**Background:** The present retrospective cross-sectional study aimed to investigate the management of latent tuberculosis infection (LTBI) in liver transplant recipients, assessing the impact of isoniazid prophylaxis on patient outcomes.

**Methods:** Data from liver transplant recipients (2013 - 2021) at Montaseriyeh Hospital, Mashhad, were analyzed. The inclusion criteria comprised patients with a positive tuberculin skin test (PPD) or interferon-gamma release assay (IGRA) in either the donor or recipient (n = 30). Demographic, clinical, and laboratory information, including the duration of isoniazid use, liver enzyme levels, and patient outcomes, was collected. Statistical analyses included descriptive statistics, non-parametric tests, and logistic regression.

**Results:** Thirty liver transplant recipients received isoniazid prophylaxis (up to 9 months). The duration of isoniazid use and liver enzyme levels did not follow a normal distribution. No significant increase was found in liver enzyme levels [serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT)] across different intervals. When examining each variable separately, higher SGOT and SGPT levels at the end of the first month after isoniazid consumption were significantly associated with increased mortality risk. The duration of isoniazid use and liver enzyme levels in subsequent months did not exhibit a significant relationship with patient survival.

**Conclusions:** Managing LTBI in liver transplant recipients presents challenges in isoniazid prophylaxis and predicting outcomes. Elevated SGOT and SGPT levels at the end of the first month after isoniazid consumption were associated with increased mortality risk. Further research is required for optimizing LTBI management in this patient population.

**Keywords:** Isoniazid, Alanine Transaminase, Tuberculin, Aspartate Aminotransferases, Glutamates, Pyruvates

## 1. Background

Tuberculosis remains a severe threat to the lives of liver transplant patients due to high fatality rates (1, 2). In this vulnerable population, tuberculosis infection is most commonly caused by the reactivation of latent infection, but it can also be transmitted from an infected organ after donation (2). However, diagnosing and treating tuberculosis in the post-transplant period involves numerous complications. Delays in diagnosis are prevalent due to unusual clinical symptoms and an elevated incidence of extra-pulmonary tuberculosis (about 60%) among solid organ recipients. Furthermore,

the lack of precise diagnostic tools complicates the diagnosis procedure. The coexistence of various medical conditions raises concerns about possible drug-drug interactions between anti-tuberculosis medication and cyclosporine, a routinely used immunosuppressive medicine in liver transplant recipients. Additionally, the risk of hepatotoxicity with anti-tuberculosis medications adds another degree of difficulty (3). Alarming statistics show that the death rate linked with tuberculosis infection in transplant patients is around 29%, highlighting its role as one of the most life-threatening infectious diseases in this population (4).

Copyright © 2025, Ghasemzadeh Rahbardar et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (<https://creativecommons.org/licenses/by/4.0/>), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

**How to Cite:** Aliakbarian M, Ghasemzadeh Rahbardar M, Barzegar Torghabeh Z, Faghani G, Khodashahi R. Latent Tuberculosis Management in Liver Transplant Recipients: Insights from a Retrospective Analysis. Arch Clin Infect Dis. 2025; 20 (5): e158129. <https://doi.org/10.5812/archcid-158129>.

Immunosuppression is an established risk factor for tuberculosis recurrence, particularly in the context of organ transplantation. Tuberculosis infection occurs in approximately 1.2 - 6.4% of transplant cases worldwide, with frequency reaching 15% in tuberculosis-endemic countries (5). Reactivation of latent tuberculosis infection (LTBI) is the most common type of tuberculosis presentation after transplantation (2). In the general population, 5 - 10% of people with healthy immune systems who have been exposed to *Mycobacterium tuberculosis* will develop active tuberculosis at some point throughout their lives. However, this risk increases dramatically, with estimates ranging from 10 to 70 times greater in persons undertaking immunosuppressive regimens, such as transplant recipients (2, 6).

Prophylactic use of isoniazid is recommended for high-risk populations (7). Isoniazid is an antibiotic prescribed for the treatment and prevention of tuberculosis. It is frequently used in combination with other medications to prevent the development of drug-resistant tuberculosis (8). This medicine suppresses the growth of bacteria and is only effective against infections caused by bacteria, not viral diseases such as the common cold or the flu. Isoniazid attacks *M. tuberculosis* by inhibiting the formation of mycolic acid, a key component of the bacterial cell wall (9).

## 2. Objectives

Therefore, the present study aimed to investigate the treatment, management, and prognosis of LTBI in liver transplant recipients at Montaseriyeh Hospital in Mashhad, during the years 2013 - 2021. This was achieved by conducting a comprehensive review of the medical records of 450 liver transplant patients, which provided valuable insights into the donor-recipient purified protein derivative (PPD) and interferon-gamma release assay (IGRA) results, details of prophylaxis drug type and dosage, duration of previous LTBI treatment, as well as the patient's prognosis during the 36-month follow-up period after transplantation. By examining these factors, the study aimed to contribute to the development of effective strategies for the prevention and management of tuberculosis in liver transplant recipients, ultimately improving patient outcomes and reducing the incidence of tuberculosis-related complications and mortality.

## 3. Methods

### 3.1. Study Approval and Data Extraction

The study was approved by the Ethics Committee of Mashhad University of Medical Sciences ([IR.MUMS.MEDICAL.REC.1400.639](https://doi.org/10.30467/mums.medical.rec.1400.639)). Data for this retrospective cross-sectional study were extracted from the archives of Montaseriyeh Hospital, Mashhad. The information referred to liver transplant recipients between the years 2013 - 2021. The data extraction involved a review of patients' paper files and accessing the hospital information system (HIS). Initially, all files of liver transplant recipients during the 8 years were reviewed. Patients who exhibited a positive PPD IGRA response in either the donor or recipient were included in the study. In cases where the information in the files was incomplete, efforts were made to supplement the missing details by directly contacting the patients or conducting personal visits. Patients were assured of the confidentiality of their information, which would be solely used for the study.

### 3.2. Inclusion and Exclusion Criteria

The inclusion criteria for the study comprised patients who received liver transplants and had positive PPD IGRA results for either the donor or recipient. Exclusion criteria were applied to cases where hospital records were inaccurately completed or for patients who did not receive isoniazid treatment due to allergies or other reasons.

### 3.3. Data Collection

The data collection process began by recording the demographic information of each patient, including age, gender, occupation, smoking status, and length of hospital stay. Clinical and laboratory information was subsequently documented, which included the history of specific medications, presence of underlying diseases, prior history of tuberculosis, dosage and duration of isoniazid treatment, the occurrence of tuberculosis or other infections post-transplantation, diagnosed infections, performed surgeries, transplant rejection, cause of patient death (if applicable), and laboratory results such as tuberculin skin test (TST) outcomes and liver enzyme levels to assess liver toxicity.

### 3.4. Main Measurable Outcomes

The main outcome of the study was to determine the decision regarding the administration of tuberculosis latent infection prophylaxis (TBLIPI) based on the PPD IGRA response of the donor or transplant recipient. Additionally, the study aimed to assess the dose and duration of isoniazid use as prophylaxis, evaluate liver

toxicity, and examine transplant rejection after receiving isoniazid in liver transplant recipients.

### 3.5. Tuberculin Skin Test Evaluation

The results of the TST were assessed by trained infectious disease specialists at Montaseriyeh Hospital. All readings were performed 48 to 72 hours after intradermal injection of PPD. The diameter of induration (not erythema) was measured in millimeters using a transparent ruler, following standard guidelines. Only measurements showing an induration equal to or greater than the defined threshold for immunocompromised patients were considered positive.

### 3.6. Sample Size and Statistical Method

Owing to the restricted patient pool, a census sample strategy was employed, drawing from the patient files of liver recipient patients registered from 2013 to 2021. Thirty individuals were gathered for analysis.

### 3.7. Statistical Analysis

The data was described using appropriate statistical tables and indices such as the mean, standard deviation, and quartiles. The dispersion of qualitative variables was described using a bar graph, whereas the dispersion of quantitative variables was presented using a histogram. To begin, the Shapiro-Wilk test and the Q-Q plot diagram were used to check the normal distribution of the independent variables of this study at different intervals, i.e., the length of isoniazid use and the level of liver enzymes in one-month intervals over the first four months. Due to the non-normal distribution of data in the independent variables, the Friedman test was used to compare the average of liver enzymes at different times. In addition, a logistic regression statistical test was utilized to explore the semantic link between the level of liver enzymes in each period and the duration of isoniazid use with mortality rates. Python 3 was used for data analysis, and the significance level for all tests was less than 5%.

## 4. Results

The target group for this study consisted of liver transplant patients at Montaseriyeh Hospital in Mashhad during the period of 2013 - 2021. The study involved the examination of over 400 transplant patients, focusing on determining the criteria for patients to receive isoniazid. In this particular population, patients who had either a positive PPD or

IGRA test in either the recipient or transplant donor were prescribed isoniazid as a prophylactic measure for tuberculosis or LTBI. Among the patients under investigation, a total of 30 individuals met the eligibility criteria and had received isoniazid. Data about these patients were extracted for further analysis. Specifically, the collected data included the duration of isoniazid usage, which extended up to 9 months at the end of the prophylaxis period. Additionally, the levels of liver enzymes [serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT)] were recorded during the first 4 months of treatment. Furthermore, the outcomes of these patients, in terms of survival or death, were documented. In the event of patient mortality, the cause of death was also collected as part of the data ([Table 1](#) and [Figure 1](#)).

Subsequently, the collected information was subjected to analysis using appropriate methods. The description and histogram depicting the distribution of isoniazid use duration and liver enzyme levels in the studied subjects are presented in [Table 2](#) and [Figure 2](#), respectively. Based on the analysis ([Table 3](#) and [Figure 3](#)), it was observed that the data distribution for both the duration of isoniazid use and the level of liver enzymes in the studied subjects did not meet the assumption of normality. None of these variables exhibited a normal distribution at a significance level of 0.05, based on the Q-Q plot. Consequently, for future analyses, non-parametric tests, such as Friedman's test, should be employed to compare the average levels of liver enzymes across different intervals. Hence, Friedman's test was employed to compare the average levels of liver enzymes among the study subjects across different intervals. The SGOT ( $P = 0.87$ ) and SGPT ( $P = 0.78$ ) levels did not show a significant increase when compared to each other across different intervals ( $P > 0.05$ ).


When examining each variable separately in relation to the mortality status of the patients, it was found that the levels of liver enzymes SGOT and SGPT at the end of the first month after isoniazid consumption had a significant association with patient survival (SGOT1  $P = 0.02$ , SGPT1  $P = 0.01$ ). Specifically, higher levels of these liver enzymes at the end of the first month after starting isoniazid consumption were found to be significantly associated with an increased risk of mortality in patients. However, the duration of isoniazid use and the levels of liver enzymes at the end of subsequent months, excluding the first month, did not show a significant relationship with the survival status of the patients ( $P > 0.05$ ).

## 5. Discussion

**Table 1.** Logistic Regression Test to Examine the Relationship Between Duration of Isoniazid Use, Liver Enzyme Levels, and Death (Survival) Status in the Study Subjects

Variables	Coefficient	SE	Z	P-Value	CI (2.5%)	CI (97.5%)
INH duration	-2.1	1.3	-1.6	0.11	-4.7	0.5
SGOT1	-2.8	1.2	-2.3	0.021	-5.2	-0.4
SGPT1	-3.4	1.4	-2.5	0.012	-6.1	-0.7
SGOT2	-0.9	0.9	-1.1	0.254	-2.6	0.7
SGPT2	-1.2	0.7	-1.7	0.097	-2.5	0.2
SGOT3	-1.7	1.2	-1.5	0.14	-4.0	0.6
SGPT3	-1.6	0.9	-1.7	0.089	-3.5	0.2
SGOT4	-0.5	1.2	-0.4	0.69	-2.9	1.9
SGPT4	-0.8	1.2	-0.6	0.518	-3.2	1.6

Abbreviations: SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate pyruvate transaminase.


**Figure 1.** A and B, frequency of each condition in death**Table 2.** Description of the Distribution of Isoniazid Use Duration and Liver Enzyme Levels

Variables	INH Duration	SGOT1	SGPT1	SGOT2	SGPT2	SGOT3	SGPT3	SGOT4	SGPT4
Count	30.0	25.0	25.0	21.0	21.0	15.0	15.0	10.0	10.0
Mean	6.1	67.7	57.2	87.4	72.3	80.2	73.2	95.4	74.7
Std	2.1	35.9	52.8	61.4	72.5	48.8	77.3	68.8	53.6
Min	3.0	18.0	12.0	20.0	13.0	33.0	17.0	31.0	26.0
25%	4.2	45.0	33.0	38.0	29.0	52.5	39.5	45.7	42.5
50%	6.0	63.0	42.0	71.0	49.0	65.0	48.0	65.0	48.0
75%	8.7	83.0	50.0	110.0	89.0	95.5	71.5	147.2	92.5
Max	9.0	164.0	281.0	212.0	292.0	218.0	329.0	231.0	183.0

Abbreviations: SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate pyruvate transaminase.

This retrospective cross-sectional study aimed to investigate the management of LTBI in liver transplant recipients and evaluate prognostic factors related to the administration of isoniazid prophylaxis and patient outcomes. Our analysis included data from 30 liver transplant recipients who met the eligibility criteria and received isoniazid prophylaxis. The duration of isoniazid usage ranged up to 9 months. Our data showed that the distribution of isoniazid use duration

and liver enzyme levels did not follow a normal distribution. Interestingly, we observed no significant increase in liver enzyme levels (SGOT and SGPT) across different intervals. However, when examining each variable separately, higher SGOT and SGPT levels at the end of the first month after isoniazid consumption were significantly associated with increased mortality risk. The duration of isoniazid use and liver enzyme levels in



**Figure 2.** The histograms for all numerical variables

**Table 3.** Evaluation of Normal Distribution for Data Dispersion of Isoniazid Use Duration and Liver Enzyme Levels in the Study Subjects Using the Shapiro-Wilk Test

Variables	W	P-Value	Normal
INH duration	0.87	0.001	False
SGOT1	0.89	0.014	False
SGPT1	0.57	< 0.001	False
SGOT2	0.86	0.006	False
SGPT2	0.67	< 0.001	False
SGOT3	0.79	0.003	False
SGPT3	0.61	< 0.001	False
SGOT4	0.82	0.028	False
SGPT4	0.83	0.031	False


Abbreviations: SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate pyruvate transaminase.

subsequent months did not exhibit a significant relationship with patient survival.

Iran, an endemic country for tuberculosis, has a high frequency of tuberculosis infection, with 14 cases per 100,000 people (2). This situation presents a substantial difficulty for people with impaired immune systems,

especially those who have had organ transplants. The incidence of tuberculosis among organ recipients is significantly higher, ranging from 20 to 74 times that of the general population. Furthermore, individuals who had immunosuppressive treatment before transplantation have a six-fold higher chance of





**Figure 3.** The Q-Q plots for all variables checking normality assumption

acquiring tuberculosis following the surgery (2, 10). These findings highlight the significance of comprehensive tuberculosis screening before transplantation. Screening for LTBI before transplantation presents challenges, with variations in approaches among different centers. The use of the IGRA test adds complexity to the screening process, and its effectiveness on the outcomes of liver transplant recipients remains unclear. In a retrospective study, the positive rate of the QuantiFERON-Tuberculosis Gold test (QFT) before liver transplant was found to be 13.5%, while none of the positive cases progressed to active tuberculosis (10).

Despite the complexity associated with the diagnosis and treatment of latent tuberculosis, most transplant centers, including our center, perform latent tuberculosis screening and provide treatment when necessary. In a previous study in Tehran, Iran, the positive TST results in cirrhotic patients on the waiting list were 15.9% (11), which is lower than the reported rates of positive TST among liver recipients in Canada (24.2%)

(12) and Italy (44%) (13). However, in the present study, the rate of LTBI was found to be 7.5%. Latent tuberculosis treatment is essential, particularly for high-risk individuals such as solid organ transplant recipients (2). Following the transplant surgery, there was a notable decrease in the number of active tuberculosis cases since all patients in our research who tested positive for the PPD test were given prophylactic treatment. After receiving a transplant, 9 of the latent tuberculosis patients experienced active tuberculosis. Before receiving an organ transplant, latent tuberculosis patients are advised to take isoniazid once a day for nine months.

On the other hand, reports of the chemical toxicity of isoniazid are not entirely consistent (8). In transplant patients without a history of liver disease, the risk of hepatotoxicity related to isoniazid prophylaxis appears to be low, and in certain candidates for liver transplantation who have compensated hepatic disease, it may even be well tolerated (2, 14). However, it is crucial to emphasize the importance of careful monitoring for

adverse effects and the potential elevation of liver enzymes during the administration of isoniazid (14). According to a study by Moon et al., due to the risk of isoniazid-induced hepatotoxicity, it is advisable to avoid using isoniazid in the early post-liver transplant period. Instead, it is recommended to wait until the recipient's liver function has stabilized before initiating isoniazid prophylaxis in liver transplant recipients (15).

Isoniazid was successfully used in our trial to treat latent tuberculosis before liver transplantation, and no side effects were noted. Surprisingly, we found no significant rise in liver enzyme levels, particularly serum SGOT and SGPT, across different intervals. This shows that isoniazid prophylaxis may not have any significant effect on liver function in liver transplant recipients with latent tuberculosis. However, when each variable was examined separately, greater SGOT and SGPT levels at the end of the first month after isoniazid consumption were substantially related to an increased mortality risk. These findings highlight the significance of monitoring liver enzyme levels throughout the early phases of isoniazid treatment in order to identify patients at increased risk of serious side effects. The lack of a significant association between the duration of isoniazid use and liver enzyme levels in the following months showed that prolonged isoniazid treatment may have little influence on liver function in this patient population. However, it is crucial to consider individual patient characteristics and closely monitor liver enzyme levels throughout the treatment period to ensure patient safety and optimize outcomes.

### 5.1. Conclusions

Finally, our study focused on the management of LTBI in liver transplant recipients. The study found that the duration of isoniazid use varied among individuals, although there was no significant rise in liver enzyme levels (SGOT and SGPT) during the treatment period. Higher SGOT and SGPT levels at the end of the first month of isoniazid consumption were substantially related to an increased risk of mortality. These findings highlight the necessity of early monitoring of liver enzyme levels to identify patients who are at a higher risk of adverse consequences. More study is needed to improve the management of LTBI in liver transplant recipients and provide better patient care in this vulnerable population.

### 5.2. Strengths and Limitations

The inclusion of a homogeneous sample of liver transplant recipients with LTBI and the thorough examination of numerous prognostic markers, such as

the length of isoniazid use and liver enzyme levels, are two of the strongest points of our study. There are a few limitations, though, that must be noted. First, the retrospective design of the study introduces biases by design and makes it more difficult to demonstrate causation. Secondly, the limited sample size could potentially impact the applicability of our results. To validate our findings, larger sample sizes and prospective designs should be used in future research.

### Acknowledgements

We would like to thank the Transplant Research Center, Mashhad University of Medical Sciences, for providing support in this manuscript. Also, we would like to thank the Clinical Research Development Unit, Imam Reza Hospital, Mashhad University of Medical Sciences, for their assistance in this manuscript. The results presented in this paper are part of a student's thesis.

### Footnotes

**Authors' Contribution:** Study concept and design: M. A. and R. K.; Analysis and interpretation of data: M. G. R.; Drafting of the manuscript: Z. B., and M. G. R.; Critical revision of the manuscript for important intellectual content: M. A. and M. G. R.; Statistical analysis: G. F.

**Conflict of Interests Statement:** The authors declare no conflict of interests.

**Data Availability:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Ethical Approval:** The present study was approved by the Ethics Committee of Mashhad University of Medical Sciences ([IR.MUMS.MEDICAL.REC.1400.639](https://doi.org/10.1002/lt.21709)).

**Funding/Support:** This study was funded by Mashhad University of Medical Science (4001127).

**Informed Consent:** All participants provided written informed consent before participating in the study.

### References

- Holty JE, Gould MK, Meinke L, Keefe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. *Liver Transpl.* 2009;15(8):894-906. [PubMed ID: 19642133]. <https://doi.org/10.1002/lt.21709>.
- Ahmadinejad Z, Mokhtaryan M, Salami A, Talebian M, Irajian H, Ghiasvand F. Evaluation of latent tuberculosis infection in liver

- transplant recipients. *Iran J Microbiol.* 2021;**13**(2):199-203. [PubMed ID: 34540155]. [PubMed Central ID: PMC8408033]. <https://doi.org/10.18502/ijm.v13i2.5981>.
3. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. *Liver Transpl.* 2004;**10**(7):886-97. [PubMed ID: 15237373]. <https://doi.org/10.1002/lt.20137>.
  4. Naqvi A, Rizvi A, Hussain Z, Hafeez S, Hashmi A, Akhtar F, et al. Developing world perspective of posttransplant tuberculosis: morbidity, mortality, and cost implications. *Transplant Proc.* 2001;**33**(1-2):1787-8. [PubMed ID: 11267512]. [https://doi.org/10.1016/s0041-1345\(00\)02680-4](https://doi.org/10.1016/s0041-1345(00)02680-4).
  5. Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. *Clinical infectious diseases.* 2005;**40**(4):581-7.
  6. Maher D. The natural history of Mycobacterium tuberculosis infection in adults. *Tuberculosis.* 2009. p. 129-32. <https://doi.org/10.1016/b978-1-4160-3988-4.00013-5>.
  7. Chang TE, Huang YS, Chang CH, Perng CL, Huang YH, Hou MC. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis. *J Chin Med Assoc.* 2018;**81**(2):111-8. [PubMed ID: 29198550]. <https://doi.org/10.1016/j.jcma.2017.10.002>.
  8. Knoll BM, Nog R, Wu Y, Dhand A. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates. *Infection.* 2017;**45**(3):335-9. [PubMed ID: 28276008]. <https://doi.org/10.1007/s15010-017-1004-5>.
  9. Li M, Hu W, Wang L, Wei J, Sun J, Li J, et al. Study on the formation mechanism of isoniazid crystal defects and defect elimination strategy based on ultrasound. *Ultrason Sonochem.* 2021;**77**:105674. [PubMed ID: 34304118]. [PubMed Central ID: PMC8326229]. <https://doi.org/10.1016/j.ultsonch.2021.105674>.
  10. Hand J, Sigel K, Huprikar S, Hamula C, Rana M. Tuberculosis after liver transplantation in a large center in New York City: QuantiFERON®-TB Gold-based pre-transplant screening performance and active tuberculosis post-transplant. *Transplant Infectious Disease.* 2018;**20**(2). e12845.
  11. Ahmadinejad Z, Azmoudeh Ardalan F, Razzaqi M, Davoudi S, Jafarian A. QuantiFERON-TB Gold In-Tube test for diagnosis of latent tuberculosis (TB) infection in solid organ transplant candidates: a single-center study in an area endemic for TB. *Transpl Infect Dis.* 2013;**15**(1):90-5. [PubMed ID: 23173720]. <https://doi.org/10.1111/tid.12027>.
  12. Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. *Am J Transplant.* 2007;**7**(12):2797-801. [PubMed ID: 17941955]. <https://doi.org/10.1111/j.1600-6143.2007.02011.x>.
  13. Pavoni M, Biagetti C, Dal Monte P, Ballardini G, Morelli C, Sambri V, et al. Usefulness of the QuantiFERON®-TB GOLD IN TUBE test for detecting latent tuberculosis infection in patients with cirrhosis candidate for orthotopic liver transplantation (OLT). *Digestive and Liver Disease.* 2007;**39**(10):A39-40. <https://doi.org/10.1016/j.dld.2007.07.029>.
  14. Ghayumi SMA, Shamsaeefar A, Motazedian N, Mashhadiagha A, Sayadi M, Nikeghbalian S, et al. Isoniazid prophylaxis in liver transplant recipient with latent tuberculosis: Is it harmful for transplanted liver? *Transpl Infect Dis.* 2022;**24**(4). e13849. [PubMed ID: 35579604]. <https://doi.org/10.1111/tid.13849>.
  15. Moon HH, Park SY, Kim JM, Park JB, Kwon CHD, Peck KR, et al. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area. *Ann Transplant.* 2017;**22**:338-45. [PubMed ID: 28579606]. [PubMed Central ID: PMC6248040]. <https://doi.org/10.12659/aot.902989>.